Some patients with vulvar cancer can achieve clinical cure, and its prognosis is related to the stage of the disease, type of pathology, treatment method and the patient’s own situation, etc. Some studies claimed that its 5-year overall survival rate is 72%.
Vulvar cancer is a rare gynecological malignant tumor, accounting for about 4%~5% of all malignant tumors of the female reproductive system, mainly occurring in postmenopausal women at an average age of 65 years. Although vulvar cancer is easy to be detected at an early stage on the surface of the body, treatment is often delayed. Vulvar cancer is most malignant in sarcoma and malignant melanoma, followed by adenocarcinoma and squamous cell carcinoma, and least malignant in basal cell carcinoma.
Early stage vulvar cancer is mainly treated by surgery, and some patients can maintain the integrity of vulva after surgery, which can improve the quality of life of patients. If there are metastases in lymph nodes, patients often need to undergo second-stage lymph node dissection or adjuvant radiotherapy in addition to surgery in order to prolong the survival period of patients as much as possible.
The prognosis of vulvar cancer is related to the size of the tumor, specific staging, cancer site and the degree of differentiation of the tumor, and is closely related to whether there are lymph node metastases and whether effective treatment is taken.
Some studies claim that the 5-year survival rate of patients with combined lymph node metastasis is 50%, and the 5-year survival rate of patients without lymph node metastasis may be as high as 90%. There are also studies claiming that the overall 5-year survival rate is 72%, the 5-year survival rates of stage I-II and stage III-IV are 86% and 61% respectively, and the 5-year survival rates of squamous and non-squamous cancers are 73% and 79% respectively.
If vulvar cancer is found, it is recommended to go to the hospital in time to get a clear diagnosis and treatment so as not to delay the condition.